BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26506885)

  • 21. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes.
    Fukumura Y; Nakanuma Y; Kakuda Y; Takase M; Yao T
    Virchows Arch; 2017 Jul; 471(1):65-76. PubMed ID: 28550497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
    Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
    Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
    Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
    Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas.
    Furukawa T; Kuboki Y; Tanji E; Yoshida S; Hatori T; Yamamoto M; Shibata N; Shimizu K; Kamatani N; Shiratori K
    Sci Rep; 2011; 1():161. PubMed ID: 22355676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
    Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
    Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of intraductal papillary neoplasm of bile duct with respect to histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm.
    Nakanuma Y; Kakuda Y; Uesaka K; Miyata T; Yamamoto Y; Fukumura Y; Sato Y; Sasaki M; Harada K; Takase M
    Hum Pathol; 2016 May; 51():103-13. PubMed ID: 27067788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant GNAS limits tumor aggressiveness in established pancreatic cancer via antagonizing the KRAS-pathway.
    Kawabata H; Ono Y; Tamamura N; Oyama K; Ueda J; Sato H; Takahashi K; Taniue K; Okada T; Fujibayashi S; Hayashi A; Goto T; Enomoto K; Konishi H; Fujiya M; Miyakawa K; Tanino M; Nishikawa Y; Koga D; Watanabe T; Maeda C; Karasaki H; Liss AS; Mizukami Y; Okumura T
    J Gastroenterol; 2022 Mar; 57(3):208-220. PubMed ID: 35018527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. McCune Albright syndrome is a genetic predisposition to intraductal papillary and mucinous neoplasms of the pancreas associated pancreatic cancer in relation with GNAS somatic mutation - a case report.
    Gaujoux S; Pasmant E; Silve C; Mehsen-Cetre N; Coriat R; Rouquette A; Douset B; Prat F; Leroy K
    Medicine (Baltimore); 2019 Dec; 98(50):e18102. PubMed ID: 31852070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
    Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas?
    Nakanuma Y
    Pathol Int; 2010 Jun; 60(6):419-29. PubMed ID: 20518896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GNAS
    Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
    Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological Study of Resections of Intraductal Papillary Neoplasm of the Bile Duct.
    Sato T; Hisaka T; Sakai H; Ishikawa H; Kawahara R; Goto Y; Nomura Y; Yasunaga M; Fujita F; Tanigawa M; Naito Y; Akiba J; Yano H; Tanaka H; Akagi Y; Okuda K
    Anticancer Res; 2019 Aug; 39(8):4569-4573. PubMed ID: 31366561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
    Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
    Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas.
    Schnelldorfer T; Sarr MG; Nagorney DM; Zhang L; Smyrk TC; Qin R; Chari ST; Farnell MB
    Arch Surg; 2008 Jul; 143(7):639-46; discussion 646. PubMed ID: 18645105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraductal Oncocytic Papillary Neoplasms of the Pancreas.
    Kallen ME; Naini BV
    Arch Pathol Lab Med; 2016 Sep; 140(9):992-6. PubMed ID: 27575268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report.
    Verocq C; Racu ML; Bafort D; Butorano G; Perez-Casanova Garcia L; Navez J; Witterwulghe M; Sheahan K; Swan N; Closset J; Van Laethem JL; Maris C; D'Haene N
    Diagn Pathol; 2021 Dec; 16(1):117. PubMed ID: 34895278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
    Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
    Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.